Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Below 50-Day Moving Average – Here’s What Happened

Capricor Therapeutics, Inc. (NASDAQ:CAPR) passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $7.00 and traded as low as $6.70. Capricor Therapeutics shares last traded at $6.72, with a volume of 1,315,068 shares trading hands.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price target on shares of Capricor Therapeutics in a report on Thursday, September 25th. Piper Sandler reaffirmed an “overweight” rating and set a $20.00 price target on shares of Capricor Therapeutics in a report on Friday, July 11th. Alliance Global Partners reaffirmed a “buy” rating on shares of Capricor Therapeutics in a report on Monday, July 14th. Oppenheimer dropped their price target on shares of Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating on the stock in a report on Monday, June 23rd. Finally, Roth Capital dropped their price target on shares of Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $22.25.

Capricor Therapeutics Stock Down 5.2%

The company has a market cap of $307.24 million, a PE ratio of -4.10 and a beta of 0.68. The business’s fifty day moving average is $7.00 and its 200-day moving average is $8.89.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). Analysts forecast that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its position in shares of Capricor Therapeutics by 280.8% during the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,976 shares during the last quarter. Citizens Financial Group Inc. RI bought a new stake in shares of Capricor Therapeutics during the first quarter valued at approximately $95,000. Sheets Smith Investment Management bought a new stake in shares of Capricor Therapeutics during the third quarter valued at approximately $107,000. KLP Kapitalforvaltning AS raised its position in shares of Capricor Therapeutics by 65.2% during the second quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 4,300 shares during the last quarter. Finally, Arizona State Retirement System bought a new stake in shares of Capricor Therapeutics during the first quarter valued at approximately $111,000. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.